Export

EN
FR
Amphotericin B
Essential medicine status
Section:
6. Anti-infective medicines 6.3. Antifungal medicines
ATC codes: J02AA01
EMLc
Indication
Aspergillosis ICD11 code: 1F20.Z
INN
Amphotericin B
Medicine type
Chemical agent
List type
Core (EML)
(EMLc)
Additional notes
*Liposomal amphotericin B has a better safety profile than the sodium deoxycholate formulation and should be prioritized for selection and use depending on local availability and cost.
Formulations
Parenteral > General injections > IV: 50 mg in vial powder for injection (liposomal complex) ; 50 mg in vial powder for injection (as sodium deoxycholate)
EML status history
First added in 1977 (TRS 615)
Changed in 1979 (TRS 641)
Changed in 1984 (TRS 722)
Changed in 2003 (TRS 920)
Changed in 2007 (TRS 950)
Changed in 2009 (TRS 958)
Changed in 2013 (TRS 985)
Changed in 2023 (TRS 1049)
Sex
All
Age
Also recommended for children
Therapeutic alternatives
The recommendation is for this specific medicine
Patent information
Patents have expired in most jurisdictions
Wikipedia
Amphotericin B
DrugBank
Amphotericin b
Summary of evidence and Expert Committee recommendations
Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended the listing for amphotericin B on the EML and EMLc be amended to list the liposomal and deoxycholate formulations separately, and the inclusion of a note to indicate that liposomal amphotericin B is the preferred formulation because of its better safety profile.